TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: vigilance detection speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate word recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of remission
Endpoint domain: Mortality/survival
Primary endpoint: ROSA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma viral load decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CD4(+) T cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HAD total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Independent ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women pain-free during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women pain-free at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women pain-free at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bile acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of workplace smoking restrictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with smoking policy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employers' awareness of the law
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cotinine validated abstinence rates from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Plasma Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Termination of status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Regression of proximal carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recurrence rate of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Depressive mood reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance of abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol exposure (AUC0t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum arterial plasma nicotine concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean times to C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swollen Joint Count (SJC) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful functioning prosthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to reoperation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of aqueous humor flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: amount of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IQ scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HRQoL utility value (EQ index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum S100beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma ET levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: venous blood-flow augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Use of aspirin before myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of aspirin after myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of calcium antagonists after myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of algorithms for diabetes identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of algorithms for diabetes identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Predictive Value (NPV) of algorithms for diabetes identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ETT impingement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year actuarial survival rate
Endpoint domain: Mortality/survival
Primary endpoint: actuarial freedom from progression (FFP) rate
Endpoint domain: Mortality/survival
Primary endpoint: Adherence improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: all-cause mortality, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: virological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overjet increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary basal bone movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross-validation area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak cycling performance (peak power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal pH control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Enamel remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in algofunctional indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in degeneration quantified by Pfirrmann grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and free 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infections treated with antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of infections handled by physicians as 'wait and see'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effectiveness of Clo-Met in treating Candida vaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IRLS score from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with CGI-I rating of 'very much improved' or 'much improved'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of antidepressant responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean HRSD change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily subjective mood ratings post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incremental area under curve (iAUC) of plasma GIP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reducing depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survivor well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for antidepressant medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Remission rates at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricle mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in high-density lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perioperative myocardial infarctions (MIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative confusions
Endpoint domain: Adverse events/effects
Primary endpoint: Percent reduction of initial ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radial progression toward wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HBV DNA <20 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint (stroke, systemic embolism, myocardial infarction, or all-cause mortality)
Endpoint domain: Mortality/survival
Primary endpoint: improve functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in NT-pro BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Word recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-rated subjective scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of re-tear
Endpoint domain: Adverse events/effects
Primary endpoint: irreversible ischemic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Episodes of Ca x P >55 mg(2)/dl(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived usefulness of the program for people with arthritis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive therapeutic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous initiation of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Compliance Intent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understandability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of potentially lethal cancers
Endpoint domain: Mortality/survival
Primary endpoint: Water consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of borborygmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gas elimination recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Defecation recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Injury severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of head injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of limb injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal retention of BC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between trial and unblinded measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homogeneity of mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low mineralized bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported depressed affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: urinary free cortisol output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social cognitive outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Keloid blood perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of E-cadherin and ZO-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life (UW-QOL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of postoperative discomfort symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: sustained improvement in SWM performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit rates
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cumulative number of new gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mouth opening limitation (DIINC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 fever (>40.0°C)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-PhtD and anti-Ply antibody geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in CRQ domains
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in SGRQ domains
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PSA recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: self-image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CV death/myocardial infarction/stroke
Endpoint domain: Mortality/survival
Primary endpoint: CV death/heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transient increases in serum creatinine
Endpoint domain: Adverse events/effects
Primary endpoint: Healed rates of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in performing supraclavicular access to the subclavian vein
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mRS score of 0 to 2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximum increase of SCr level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hospitalization for cardiac decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in New York Heart Association functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAScalmness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum blood nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: onset of 'head rush'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving/urges to smoke
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Timed Up and Go times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of EF (Executive Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IC(50) of budesonide on ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: A(50) of budesonide on cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin sensitivity (ISGU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adoption of palmoplantar phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hyperkeratosis and acanthosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erosions and ulcerations
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confidence in performing otoscopy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of anatomical landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of constipation cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of cases who took laxative medicines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Marginal Bone Level (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nodule volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of symptoms and cosmetic complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TSSS and TOSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall use of health, justice, and income assistance services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of CLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for later dexamethasone
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chances of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal refractive power change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end-systolic volume index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non CABG-related major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Net adverse clinical events (NACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraclass correlation coefficient for MRGlu measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in severity of bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of non-drug treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial TG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of osteotomy healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tumor size regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: apoptotic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Homeostasis model assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Generic health status (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of visits to general practitioners
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Detection and recognition of high-frequency stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the frequency of SUI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body fat (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes